image
Healthcare - Medical - Devices - NASDAQ - US
$ 12.73
1.3 %
$ 1.86 B
Market Cap
-10.91
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one ATEC stock under the worst case scenario is HIDDEN Compared to the current market price of 12.7 USD, Alphatec Holdings, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one ATEC stock under the base case scenario is HIDDEN Compared to the current market price of 12.7 USD, Alphatec Holdings, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one ATEC stock under the best case scenario is HIDDEN Compared to the current market price of 12.7 USD, Alphatec Holdings, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart ATEC

image
$13.5$13.5$13.0$13.0$12.5$12.5$12.0$12.0$11.5$11.5$11.0$11.0$10.5$10.5$10.0$10.0$9.5$9.5$9.0$9.0$8.5$8.515 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '25
FINANCIALS
612 M REVENUE
26.81%
-136 M OPERATING INCOME
21.47%
-162 M NET INCOME
100.00%
-44.7 M OPERATING CASH FLOW
43.11%
-93.1 M INVESTING CASH FLOW
34.40%
56.2 M FINANCING CASH FLOW
-84.25%
169 M REVENUE
-4.31%
-44.3 M OPERATING INCOME
-85.96%
-51.9 M NET INCOME
-55.73%
-5.04 M OPERATING CASH FLOW
-47.89%
-11.6 M INVESTING CASH FLOW
-209.98%
30.8 M FINANCING CASH FLOW
-39.26%
Balance Sheet Alphatec Holdings, Inc.
image
Current Assets 417 M
Cash & Short-Term Investments 139 M
Receivables 83 M
Other Current Assets 196 M
Non-Current Assets 358 M
Long-Term Investments 0
PP&E 191 M
Other Non-Current Assets 167 M
17.90 %10.70 %25.21 %24.63 %21.56 %Total Assets$775.7m
Current Liabilities 153 M
Accounts Payable 53 M
Short-Term Debt 1.66 M
Other Current Liabilities 98.4 M
Non-Current Liabilities 637 M
Long-Term Debt 575 M
Other Non-Current Liabilities 62.3 M
6.71 %12.46 %72.74 %7.89 %Total Liabilities$789.9m
EFFICIENCY
Earnings Waterfall Alphatec Holdings, Inc.
image
Revenue 612 M
Cost Of Revenue 187 M
Gross Profit 424 M
Operating Expenses 560 M
Operating Income -136 M
Other Expenses 26 M
Net Income -162 M
700m700m600m600m500m500m400m400m300m300m200m200m100m100m00(100m)(100m)(200m)(200m)612m(187m)424m(560m)(136m)(26m)(162m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
69.37% GROSS MARGIN
69.37%
-22.27% OPERATING MARGIN
-22.27%
-26.51% NET MARGIN
-26.51%
1144.21% ROE
1144.21%
-20.90% ROA
-20.90%
-21.82% ROIC
-21.82%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Alphatec Holdings, Inc.
image
00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)(140m)(140m)(160m)(160m)(180m)(180m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -162 M
Depreciation & Amortization 83.3 M
Capital Expenditures -93.1 M
Stock-Based Compensation 0
Change in Working Capital -67.3 M
Others -44.7 M
Free Cash Flow -138 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Alphatec Holdings, Inc.
image
Wall Street analysts predict an average 1-year price target for ATEC of $16.5 , with forecasts ranging from a low of $8 to a high of $19 .
ATEC Lowest Price Target Wall Street Target
8 USD -37.16%
ATEC Average Price Target Wall Street Target
16.5 USD 29.62%
ATEC Highest Price Target Wall Street Target
19 USD 49.25%
Price
Max Price Target
Min Price Target
Average Price Target
202018181616141412121010886644Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 14
6. Ownership
Insider Ownership Alphatec Holdings, Inc.
image
Sold
0-3 MONTHS
3.74 M USD 3
3-6 MONTHS
6.9 M USD 5
6-9 MONTHS
1.61 M USD 2
9-12 MONTHS
547 K USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
1.15 M USD 4
9-12 MONTHS
7. News
Bowman Secures Contract for ATEC Parkway Development in The Aurora Highlands, CO RESTON, Va., May 20, 2025 (GLOBE NEWSWIRE) -- Bowman Consulting Group Ltd. globenewswire.com - 4 weeks ago
Alphatec Holdings, Inc. (ATEC) Q1 2025 Earnings Call Transcript Alphatec Holdings, Inc. (NASDAQ:ATEC ) Q1 2025 Earnings Conference Call May 1, 2025 4:30 PM ET Company Participants Pat Miles - Chairman and CEO Todd Koning - CFO Conference Call Participants Brooks O'Neil - Lake Street Capital Markets Vik Chopra - Wells Fargo Matt Miksic - Barclays Mathew Blackman - Stifel Young Li - Jefferies Eric Anderson - TD Cowen David Saxon - Needham Sean Lee - H.C. Wainwright Operator Good afternoon, everyone, and welcome to the webcast of ATEC's First Quarter Financial Results. seekingalpha.com - 1 month ago
Alphatec (ATEC) Reports Q1 Loss, Tops Revenue Estimates Alphatec (ATEC) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.34 per share a year ago. zacks.com - 1 month ago
ATEC Reports First Quarter 2025 Financial Results and Raises Full-Year Guidance CARLSBAD, Calif.--(BUSINESS WIRE)--Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced financial results for the quarter ended March 31, 2025, and recent corporate highlights. First Quarter 2025 Financial Results   Quarter Ended March 31, 2025 Total revenue $169 million GAAP gross margin 69% Non-GAAP gross margin 70% GAAP operating expenses $160 million Non-GAAP operating expenses $124 million GAA. businesswire.com - 1 month ago
ATEC Launches PTP™ Corpectomy, The Next Evolution of Lateral Approach Surgery CARLSBAD, Calif.--(BUSINESS WIRE)--Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced the commercial launch of its Prone TransPsoas (PTP™) Corpectomy system. This milestone marks the continued evolution of ATEC's PTP surgical approach, expanding its capabilities to include deformity and corpectomy procedures for complex pathologies of the thoracolumbar spine. “PTP Corpectomy represents a signific. businesswire.com - 1 month ago
Alphatec Holdings: Business Has Reached An Inflection Point - Buy The Dip In recent years, Alphatec Holdings or "ATEC" has outperformed sales expectations on a regular basis and successfully taken share in the $8 billion U.S. spinal disorder treatment market. The company continues to benefit from M&A-related disruptions at key competitors, which has created opportunities for ATEC to grab additional market share. Following years of elevated cash usage, the company managed to generate free cash flow in the final quarter of 2024. seekingalpha.com - 3 months ago
ATEC Prices Upsized $350.0 Million Convertible Senior Notes Offering CARLSBAD, Calif.--(BUSINESS WIRE)--Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced the pricing of its offering of $350,000,000 aggregate principal amount of 0.75% convertible senior notes due 2030 (the “notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The offering size was increased from t. businesswire.com - 3 months ago
Alphatec Holdings, Inc. (ATEC) Q4 2024 Earnings Call Transcript Alphatec Holdings, Inc. (NASDAQ:ATEC ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Pat Miles - Chairman and CEO Todd Koning - CFO Conference Call Participants Brooks O'Neil - Lake Street Capital Markets Vik Chopra - Wells Fargo Eric Anderson - TD Cowen Phillip Dantoin - Piper Sandler Matt Miksic - Barclays Caitlin Cronin - Canaccord Genuity Jason Wittes - ROTH David Saxon - Needham Kallum Titchmarsh - Morgan Stanley Operator Good afternoon, everyone, and welcome to the webcast of ATEC's Fourth Quarter Financial Results. We would like to remind everyone that participants on the call will make forward-looking statements. seekingalpha.com - 3 months ago
Alphatec (ATEC) Reports Q4 Loss, Tops Revenue Estimates Alphatec (ATEC) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.37 per share a year ago. zacks.com - 3 months ago
ATEC to Participate in Upcoming Conferences CARLSBAD, Calif.--(BUSINESS WIRE)--Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today that management will participate in the following investor conferences: The Canaccord Genuity Musculoskeletal Conference in San Diego, CA, on March 10 2025, with a fireside chat at 10:30am PT The Barclays Global Healthcare Conference in Miami, FL, on March 11, 2025, with a fireside chat at 3:00pm ET If available. businesswire.com - 3 months ago
Alphatec (ATEC) Moves 9.1% Higher: Will This Strength Last? Alphatec (ATEC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. zacks.com - 5 months ago
Wall Street Analysts Predict a 73.42% Upside in Alphatec (ATEC): Here's What You Should Know The consensus price target hints at a 73.4% upside potential for Alphatec (ATEC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. zacks.com - 5 months ago
8. Profile Summary

Alphatec Holdings, Inc. ATEC

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 1.86 B
Dividend Yield 0.00%
Description Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders. The company offers SafeOp Neural InformatiX System, an Alpha InformatiX product platform designed to reduce the risk of intraoperative nerve injury; Sigma transforaminal lumbar interbody fusion pedicle-based access system that provides direct visualization of anatomical landmarks; Sigma PTP Access and Patient Positioning System; squadron lateral retractor designed to maximize patient outcomes; Invictus Spinal Fixation System, a thoracolumbar fixation system to treat a range of pathologies; and Invictus MIS SingleStep System that provides minimally invasive pedicle screw placement. It also provides Invictus Modular Fixation Systems designed to increase adaptability with the power of screw modularity; OsseoScrew system to restore the integrity of the spinal column; Arsenal spinal fixation system, a comprehensive thoracolumbar fixation platform to fix a range of degenerative to deformity pathologies and surgical procedures; Aspida Anterior Lumbar Plating System, a fixation system for anterior lumbar interbody fusion; AMP Anti-Migration Plate; OCT Spinal Fixation System; trestle luxe anterior cervical plate system; and Insignia Anterior Cervical Plate System. In addition, the company offers IdentiTi Porous Ti, Transcend Lateral, and Battalion Posterior Interbody Implants; and biologics consisting of Cervical Structural Allograft Spacers, 3D ProFuse Demineralized Bone Scaffold, Neocore Osteoconductive Matrix, Alphagraft Demineralized and Cellular Bone Matrix, and Amnioshield Amniotic Tissue Barrier, as well as EOS imaging products. It sells its products through a network of independent distributors and direct sales representatives in the United States. The company was founded in 1990 and is headquartered in Carlsbad, California.
Contact 1950 Camino Vida Roble, Carlsbad, CA, 92008 https://www.atecspine.com
IPO Date June 12, 2006
Employees 867
Officers Mr. Ali Shorooghi Senior Vice President of Marketing Mr. Scott Lish Chief Operating Officer Mr. David P. Sponsel Executive Vice President of Sales Mr. Jonathan Allen Executive Vice President of Commercial Operations Mr. J. Todd Koning Executive Vice President & Chief Financial Officer Mr. Robert Judd Vice President of Finance and Investor Relations & Controller Mr. Craig E. Hunsaker Executive Vice President of People and Culture Mr. Tyson Eliot Marshall General Counsel & Corporate Secretary Dr. Luiz Pimenta Chief Medical Officer Mr. Patrick S. Miles Executive Chairman, Chief Executive Officer & President